Aveanna Healthcare Holdings, Inc.: Form 10-Q for the period ended Sep 28, 2024
Filed with the SEC on Nov 7, 2024 and accepted by EDGAR at Nov 7, 2024, 11:33 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-06-30 to 2024-09-28 | $509.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-12-31 to 2024-09-28 | $1.50bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months2024-06-30 to 2024-09-28 | $159.7m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-12-31 to 2024-09-28 | $463.8m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-06-30 to 2024-09-28 | $88.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-12-31 to 2024-09-28 | $264.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-06-30 to 2024-09-28 | $34.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-12-31 to 2024-09-28 | $94.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-06-30 to 2024-09-28 | $39.2m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-12-31 to 2024-09-28 | $118.5m | us-gaap:InterestExpense |
| Income tax | 3 months2024-06-30 to 2024-09-28 | $15.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-12-31 to 2024-09-28 | $18.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-06-30 to 2024-09-28 | −$42.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-12-31 to 2024-09-28 | −$40.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-06-30 to 2024-09-28 | −$0.22 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-12-31 to 2024-09-28 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-06-30 to 2024-09-28 | −$0.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-12-31 to 2024-09-28 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-06-30 to 2024-09-28 | 193,361,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-12-31 to 2024-09-28 | 192,734,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-12-31 to 2024-09-28 | $19.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-09-28 | $78.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-28 | $381.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-28 | $1.64bn | us-gaap:Assets |
| Current liabilities | At period end2024-09-28 | $406.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-28 | $1.80bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-09-28 | $1.28bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-09-28 | $9.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-09-28 | −$156.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-122748. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.